![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
MK-5172, a Second Generation HCV NS3/4A Protease Inhibitor is Active Against Common Resistance Associated Variants
(RAVs) and Exhibits Cross-Genotype Activity
|
|
|
Reported by Jules Levin AASLD 2011 San Francisco Nov 6-9
Donald Graham, Adriana Acosta, Zhuyan Guo, John A. Howe, Robert Ogert, Michael Miller, Daria Hazuda, David Olsen, Steven Ludmerer,
Julie M Strizki and Richard J.O. Barnard
Merck and Co, Whitehouse Station, NJ, USA
![AASLD1.gif](../images/110711/110711-3/AASLD1.gif)
![AASLD2.gif](../images/110711/110711-3/AASLD2.gif)
![AASLD3.gif](../images/110711/110711-3/AASLD3.gif)
![AASLD4.gif](../images/110711/110711-3/AASLD4.gif)
![AASLD5.gif](../images/110711/110711-3/AASLD5.gif)
![AASLD6.gif](../images/110711/110711-3/AASLD6.gif)
![AASLD7.gif](../images/110711/110711-3/AASLD7.gif)
![AASLD8.gif](../images/110711/110711-3/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|